JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Long-term evaluation of postorchiectomy irradiation for stage I seminoma.

Radiology 1994 June
PURPOSE: To determine the late clinical effects of irradiation in stage I seminoma.

MATERIALS AND METHODS: From 1966 to 1991, 104 patients with stage I seminoma were treated and followed up. After inguinal orchiectomy, all underwent megavoltage infradiaphragmatic irradiation through a "hockey stick" field encompassing the periaortic and ipsilateral iliac lymph nodes (30 Gy in 1.5-Gy fractions).

RESULTS: There were no serious, acute toxic effects or late complications. Three patients developed tumor recurrence at 9, 10, and 17 months; two had no evident disease 5 and 25 years after salvage chemotherapy and radiation therapy. Six patients developed second malignancies a mean of 10 years after treatment. None were considered to be radiation induced, and five of these patients had no evident disease after appropriate treatment.

CONCLUSION: The first course of postorchiectomy irradiation controls stage I seminoma in most patients (101 of 104 [97.1%]) and causes no serious, acute toxic effects or late complications.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app